Opportunity Information: Apply for PAR 22 040
The NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required), Funding Opportunity Number PAR-22-040, is a National Institutes of Health grant mechanism designed to help exceptional postdoctoral fellows and research trainees currently working in the NHLBI Division of Intramural Research move into independent, tenure-track (or equivalent) research careers at extramural institutions. The core idea is to create a structured, well-supported bridge from an intramural NIH training environment to an independent faculty-style role outside NIH, so that promising investigators can carry their research programs forward and establish themselves as new, competitive extramural researchers in areas aligned with NHLBI priorities in heart, lung, blood, and sleep research.
The award is organized into two connected phases spanning up to five total years of support. The first phase is a mentored intramural period of up to two years, during which the awardee remains within NHLBI intramural research and continues to build scientific skills, productivity, and a coherent line of investigation with guidance from mentors. The second phase is an extramural period of three years that begins only after the awardee secures a position at an eligible U.S. extramural institution and receives NHLBI approval to transition. This extramural phase is meant to function as a launchpad for independence, supporting the early-stage investigator as they establish a lab or research program, generate publications and preliminary data, and compete for longer-term independent research funding.
A key point is that the move from the intramural phase to the extramural phase is not automatic. NHLBI requires a formal progress review to determine whether the intramural portion has been successful enough to justify release of the extramural phase support. That review considers research accomplishments during the mentored period and also evaluates the proposed research plan to be carried out at the new extramural institution. In practical terms, awardees need to demonstrate strong momentum during the intramural years and present a credible, well-developed plan for the independent program they will run once they transition.
This particular K22 is labeled "Clinical Trial Required," which signals that the supported research is expected to include a clinical trial component consistent with NIH definitions and policy. Applicants generally need to ensure their proposed work fits the clinical trial expectations described in the announcement and NIH rules, including appropriate oversight and reporting when applicable.
Eligibility is tightly constrained. It is specifically intended for postdoctoral fellows and research trainees in the NHLBI Division of Intramural Research who are preparing to transition to extramural independence. On the institutional side, eligible applicant organizations include public and state-controlled institutions of higher education, and the opportunity explicitly excludes non-U.S. entities. Foreign institutions cannot apply, non-U.S. components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. In other words, the transition and the extramural phase are intended to take place within eligible U.S.-based institutions and structures.
Administrative details from the listing include that it is a discretionary NIH grant within the health activity category, associated with CFDA numbers 93.233 and 93.837 through 93.840. The original closing date listed is 2024-07-12, and the funding opportunity was created on 2021-10-12. The public summary does not provide an award ceiling or expected number of awards in the fields shown, so those details would typically need to be confirmed directly in the full funding announcement and any linked NHLBI guidance.
Overall, this K22 is best understood as a competitive, milestone-gated transition award for NHLBI intramural trainees who are ready to step into independence. It provides time and structure for mentored development inside NHLBI, then conditional support to help establish an independent research program at a U.S. extramural institution, with progression dependent on demonstrated success and an approved extramural research plan.Apply for PAR 22 040
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840.
- This funding opportunity was created on 2021-10-12.
- Applicants must submit their applications by 2024-07-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required) - PAR-22-040
What is PAR-22-040 (NHLBI K22 Clinical Trial Required)?
PAR-22-040 is a National Institutes of Health (NIH) funding opportunity from the National Heart, Lung, and Blood Institute (NHLBI) that supports exceptional NHLBI intramural postdoctoral fellows and research trainees as they transition into independent, tenure-track (or equivalent) research positions at eligible U.S. extramural institutions. The goal is to bridge an NIH intramural training environment to an independent faculty-style role outside NIH, aligned with NHLBI priorities in heart, lung, blood, and sleep research.
Who is this award designed for?
This K22 is specifically intended for postdoctoral fellows and research trainees currently working in the NHLBI Division of Intramural Research who are preparing to move into independent extramural research careers.
What is the main purpose of this K22 mechanism?
The award is meant to provide a structured, well-supported pathway from mentored intramural research training to independent extramural research. It is designed to help promising investigators carry their research programs forward, establish themselves as new extramural researchers, and build competitiveness for longer-term independent funding.
How is the award structured?
The award has two connected phases spanning up to five total years:
- Phase 1: A mentored intramural period of up to two years within the NHLBI intramural program.
- Phase 2: An extramural period of three years at an eligible U.S. extramural institution, beginning only after securing a qualifying position and obtaining NHLBI approval to transition.
How long can support last under this award?
Support can last up to five years total, combining up to two years in the intramural mentored phase and three years in the extramural independent phase.
What happens during the intramural (mentored) phase?
During the intramural phase (up to two years), the awardee remains within NHLBI intramural research, continuing to develop scientific skills, build productivity, and refine a coherent line of investigation under mentorship. The intent is to demonstrate momentum and readiness for independence before transitioning.
What happens during the extramural (independent) phase?
The extramural phase (three years) is intended to serve as a launchpad for independence at an eligible U.S. extramural institution. It supports the early-stage investigator as they establish a research program, generate publications and preliminary data, and position themselves to compete for longer-term independent research funding.
Is the transition from the intramural phase to the extramural phase automatic?
No. The transition is not automatic. NHLBI requires a formal progress review to determine whether the intramural portion has been successful enough to release the extramural phase support.
What does NHLBI evaluate during the progress review for transition?
The progress review considers research accomplishments achieved during the mentored intramural period and evaluates the proposed research plan to be carried out at the new extramural institution. Awardees are expected to show strong momentum and present a credible, well-developed plan for an independent program.
When does the extramural phase begin?
The extramural phase begins only after the awardee secures a position at an eligible U.S. extramural institution and receives NHLBI approval to transition following the required review.
What does "Clinical Trial Required" mean for this K22?
"Clinical Trial Required" indicates that the supported research is expected to include a clinical trial component consistent with NIH definitions and policy. Applicants generally need to ensure their proposed work fits the clinical trial expectations described in the funding announcement and applicable NIH rules, including oversight and reporting when relevant.
Who is eligible to apply?
Eligibility is tightly constrained to postdoctoral fellows and research trainees in the NHLBI Division of Intramural Research who are preparing to transition to extramural independence.
What institutions are eligible for the extramural phase?
Eligible applicant organizations include U.S.-based public and state-controlled institutions of higher education, as specified in the opportunity summary. The transition and extramural phase are intended to occur within eligible U.S. institutions and structures.
Are non-U.S. institutions eligible to apply?
No. Non-U.S. entities are explicitly excluded. Foreign institutions cannot apply.
Are foreign components or non-U.S. components allowed?
No. Non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
What research areas does this opportunity prioritize?
The opportunity is aligned with NHLBI priorities in heart, lung, blood, and sleep research. It is intended to help trainees develop and carry forward research programs that fit within these mission areas.
What type of career endpoint is this award intended to support?
The award is intended to support a transition to an independent, tenure-track (or equivalent) research career at an extramural institution.
What is the Funding Opportunity Number for this program?
The Funding Opportunity Number is PAR-22-040.
What is the closing date listed for this opportunity?
The original closing date listed in the provided summary is 2024-07-12.
When was this funding opportunity created?
The funding opportunity was created on 2021-10-12.
What NIH category does this grant fall under?
It is described as a discretionary NIH grant within the health activity category.
What CFDA numbers are associated with this opportunity?
The listing associates this opportunity with CFDA numbers 93.233 and 93.837 through 93.840.
Does the provided summary list an award ceiling or expected number of awards?
No. The public summary provided does not include an award ceiling or an expected number of awards in the fields shown. Those details would typically need to be confirmed in the full funding announcement and any linked NHLBI guidance.
What makes this award "milestone-gated" or conditional?
The award is milestone-gated because continuation into the three-year extramural phase depends on a formal NHLBI progress review. Release of extramural support is conditional on demonstrating strong intramural accomplishments and submitting an approved, credible extramural research plan.
What is the overall takeaway for prospective applicants?
This K22 is best understood as a competitive transition award for NHLBI intramural trainees who are ready to step into independence. It provides mentored development time within NHLBI and conditional support to help establish an independent program at an eligible U.S. extramural institution, with progression dependent on demonstrated success and NHLBI approval.
Browse more opportunities from the same category: Health
Next opportunity: HEAL Initiative: National K12 Clinical Pain Career Development Program (K12 Clinical Trial Not Allowed)
Previous opportunity: Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 040
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 040) also looked into and applied for these:
| Funding Opportunity |
|---|
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) Apply for PAR 22 038 Funding Number: PAR 22 038 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed) Apply for RFA AI 21 070 Funding Number: RFA AI 21 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Expanding Differentiated Care Approaches for Adolescents Living with HIV (R01 Clinical Trial Optional) Apply for RFA MH 22 105 Funding Number: RFA MH 22 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Digital Health Strengthening in Eswatini Apply for RFI67421ESWATINIHEALTHINFORMATIONSYSTEM Funding Number: RFI67421ESWATINIHEALTHINFORMATIONSYSTEM Agency: South Africa USAID-Pretoria Category: Health Funding Amount: Case Dependent |
| Enhanced Interpersonal Focused Strategies for Suicide Prevention Interventions (R34 Clinical Trial Required) Apply for RFA MH 22 125 Funding Number: RFA MH 22 125 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens (R01 Clinical Trial Not Allowed) Apply for RFA AI 21 075 Funding Number: RFA AI 21 075 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Expanding Differentiated Care Approaches for Adolescents Living with HIV (R34 Clinical Trial Optional) Apply for RFA MH 22 106 Funding Number: RFA MH 22 106 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional) Apply for RFA AG 23 001 Funding Number: RFA AG 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cellular Senescence Network: Murine Tissue Mapping Centers (U54 - Clinical Trial Not Allowed) Apply for RFA RM 22 003 Funding Number: RFA RM 22 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Potential New Care and Treatment (C&T) Health Activity. Apply for 72051722RFICT00001 Funding Number: 72051722RFICT00001 Agency: Dominican Republic USAID-Santo Domingo Category: Health Funding Amount: Case Dependent |
| Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 22 005 Funding Number: RFA RM 22 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed) Apply for RFA AG 23 002 Funding Number: RFA AG 23 002 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 22 004 Funding Number: RFA RM 22 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional) Apply for PAR 22 053 Funding Number: PAR 22 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Apply for PAR 22 054 Funding Number: PAR 22 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Prodromal Synaptic and Circuit Changes that Contribute to AD/ADRD Onset and Progression (R01 Clinical Trial Not Allowed) Apply for PAR 22 059 Funding Number: PAR 22 059 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| RePORT International Coordinating Center (RICC) (U01 Clinical Trial Not Allowed) Apply for RFA AI 21 078 Funding Number: RFA AI 21 078 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed) Apply for RFA AG 22 026 Funding Number: RFA AG 22 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) Apply for PAR 22 030 Funding Number: PAR 22 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) Apply for PAR 22 028 Funding Number: PAR 22 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 040", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.